Revenio Group Corporation
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Probes that are accessories of iCare tonometer for measuring intraocular pre… Read more
Market Cap & Net Worth: Revenio Group Corporation (REG1V)
Revenio Group Corporation (HE:REG1V) has a market capitalization of $483.34 Million (€470.87 Million) as of March 18, 2026. Listed on the HE stock exchange, this Finland-based company holds position #10473 globally and #21 in its home market, demonstrating a -1.99% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Revenio Group Corporation's stock price €17.70 by its total outstanding shares 26602985 (26.60 Million).
Revenio Group Corporation Market Cap History: 2015 to 2026
Revenio Group Corporation's market capitalization history from 2015 to 2026. Data shows growth from $216.81 Million to $483.34 Million (9.56% CAGR).
Revenio Group Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Revenio Group Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
7.01x
Revenio Group Corporation's market cap is 7.01 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
39.24x
Revenio Group Corporation's market cap is 39.24 times its annual earnings
1.95x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $216.81 Million | $20.25 Million | $6.50 Million | 10.71x | 33.37x |
| 2016 | $235.40 Million | $23.43 Million | $5.58 Million | 10.05x | 42.16x |
| 2017 | $284.28 Million | $26.79 Million | $6.85 Million | 10.61x | 41.50x |
| 2018 | $315.94 Million | $30.66 Million | $8.10 Million | 10.31x | 38.99x |
| 2019 | $671.96 Million | $49.47 Million | $9.34 Million | 13.58x | 71.92x |
| 2020 | $1.32 Billion | $61.07 Million | $13.36 Million | 21.65x | 98.95x |
| 2021 | $1.47 Billion | $78.78 Million | $17.32 Million | 18.65x | 84.81x |
| 2022 | $1.03 Billion | $96.98 Million | $21.75 Million | 10.60x | 47.26x |
| 2023 | $731.54 Million | $96.58 Million | $19.11 Million | 7.57x | 38.28x |
| 2024 | $725.83 Million | $103.50 Million | $18.50 Million | 7.01x | 39.24x |
Competitor Companies of REG1V by Market Capitalization
Companies near Revenio Group Corporation in the global market cap rankings as of March 18, 2026.
Key companies related to Revenio Group Corporation by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
Revenio Group Corporation Historical Marketcap From 2015 to 2026
Between 2015 and today, Revenio Group Corporation's market cap moved from $216.81 Million to $ 483.34 Million, with a yearly change of 9.56%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €483.34 Million | -20.98% |
| 2025 | €611.68 Million | -15.73% |
| 2024 | €725.83 Million | -0.78% |
| 2023 | €731.54 Million | -28.85% |
| 2022 | €1.03 Billion | -30.01% |
| 2021 | €1.47 Billion | +11.10% |
| 2020 | €1.32 Billion | +96.77% |
| 2019 | €671.96 Million | +112.69% |
| 2018 | €315.94 Million | +11.14% |
| 2017 | €284.28 Million | +20.76% |
| 2016 | €235.40 Million | +8.57% |
| 2015 | €216.81 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Revenio Group Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $483.34 Million USD |
| MoneyControl | $483.34 Million USD |
| MarketWatch | $483.34 Million USD |
| marketcap.company | $483.34 Million USD |
| Reuters | $483.34 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.